<DOC>
	<DOC>NCT01632150</DOC>
	<brief_summary>The purpose of this study is to determine the safety and tolerability of elotuzumab administered in combination with thalidomide and dexamethasone in the treatment of relapsed and/or refractory multiple myeloma.</brief_summary>
	<brief_title>Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Key Confirmed diagnosis of previously treated multiple myeloma with progression documented by criteria of the International Myeloma Working Group after or during the most recent therapy Patient received 5 or fewer prior lines of therapy Eastern Cooperative Oncology Group performance status of 0 or 1 (safety leadin cohort) or 0 to 2 (additional patients) Measurable disease as defined by at least 1 of the following: Serum immunoglobulin (Ig)G, IgA, IgM, or monoclonal (M) protein level ≥0.5 g/dL or serum IgD M protein level ≥0.05 g/dL; or Urine M protein level ≥200 mg excreted in a 24hour collection sample; or Involved serum free light chain level ≥10 mg/dL, provided the free light chain ratio is abnormal Key Solitary bone or solitary extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia Monoclonal gammopathy of undetermined significance, smoldering myeloma, or Waldenström's macroglobulinemia Left ventricular ejection fraction by echocardiogram or Multi Gated Acquisition ≤50% Electrocardiogram finding of QTc ≥450 msec Active plasma cell leukemia (defined as either 20% of peripheral white blood cells, composed of plasma/CD138+ cells or an absolute plasma cell count of 2*10^9/L) Diagnosis of nonsecretory myeloma Active hepatitis A, B, or C virus infection Grade ≥2 neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>